AgomAb Therapeutics (NASDAQ:AGMB) Hits New 1-Year Low – What’s Next?

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) reached a new 52-week low during trading on Thursday . The stock traded as low as $12.61 and last traded at $12.9320, with a volume of 445557 shares trading hands. The stock had previously closed at $13.85.

Analyst Upgrades and Downgrades

AGMB has been the subject of a number of research reports. Morgan Stanley began coverage on shares of AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 target price for the company. Wall Street Zen upgraded AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Zacks Research raised AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners assumed coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $36.00 target price on the stock. Finally, JPMorgan Chase & Co. initiated coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $32.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

AgomAb Therapeutics Trading Down 4.0%

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.